Cargando…
Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
KRAS has proven difficult to target pharmacologically. Two strategies have recently been described for covalently targeting the most common KRAS mutant in lung cancer, KRAS G12C. Previously, we developed a computational model of the processes that regulate Ras activation. Here, we use this model to...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980551/ https://www.ncbi.nlm.nih.gov/pubmed/29484842 http://dx.doi.org/10.1002/psp4.12291 |